Stocks Health care TLX
NASDAQ · Health careTelix Pharmaceuticals Ltd (TLX)
Telix Pharmaceuticals Ltd reported revenue of $803.8M in fiscal 2025, up 55.6% from a year earlier. It posted a net loss of $7.1M. In fiscal 2025 capital spending exceeded operating cash flow by $43M. At December 31, 2025 it held $141.9M in cash against $405M of debt. Its latest periodic report to the SEC is the annual report (foreign issuer, amended) (20-F/A) filed on March 20, 2026.
Key facts about Telix Pharmaceuticals Ltd
- Net worth
- Telix Pharmaceuticals Ltd has a market value (market cap) of $3.8B at the latest share price, and shareholders' equity of $415.4M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $803.8M (+55.6% year on year), with a net loss of $7.1M.
- Cash flow
- In fiscal 2025 operations used $17.3M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer, amended), 20-F/A) was filed with the SEC on March 20, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Telix Pharmaceuticals Ltd does
Telix Pharmaceuticals Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TLX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $803.8M | -$7.1M | -$0.02 | -$43M |
| 2025 | $516.6M | $33.7M | $0.10 | $18.4M |
| 2023 | $333M | $4.2M | $0.01 | $8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TLX ranks in Health care
Latest SEC filings
What Telix Pharmaceuticals Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 30, 2026
- September 21, 2026
- September 14, 2026
- September 2, 2026
- September 1, 2026
- August 20, 2026
- July 21, 2026
- July 2, 2026
- May 21, 2026
- April 23, 2026
Insider trades
What the people running Telix Pharmaceuticals Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $20K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 7, 2026 | Smith Darren CharltonGroup Chief Financial Officer | Bought | 2,071 | $20K |
| April 29, 2026 | Behrenbruch ChristianMD & Group CEO, Director | Boughtindirect | 33,435 | $497.2K |
| April 28, 2026 | Behrenbruch ChristianMD & Group CEO, Director | Boughtindirect | 34,500 | $499.6K |
| March 29, 2026 | Smith Darren CharltonGroup Chief Financial Officer | Exercised options | 1,111 | - |
Who owns TLX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Behrenbruch Christian13G, passive with 1 related filers | 6.97% | February 14, 2025 |
| Kluge Andreas13G, passive with 1 related filers | 6.78% | February 14, 2025 |
Largest institutional holders
Insiders
2 insiders reported holding 20,756,927 shares in total, about $234.3M at the last price.
| Holder | Shares |
|---|---|
| Behrenbruch ChristianMD & Group CEO, Director | 20,742,93520,742,935 held indirectly |
| Smith Darren CharltonGroup Chief Financial Officer | 13,992 |
Questions about TLX
What does Telix Pharmaceuticals Ltd do?
Telix Pharmaceuticals Ltd is a company in the Health care sector, listed on NASDAQ as TLX. Its shares trade on NASDAQ under the ticker TLX.
What is Telix Pharmaceuticals Ltd's net worth?
Telix Pharmaceuticals Ltd has a market value (market cap) of $3.8B at the latest share price, and shareholders' equity of $415.4M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Telix Pharmaceuticals Ltd profitable?
No. In fiscal 2025 it reported a net loss of $7.1M on revenue of $803.8M.
How much revenue does Telix Pharmaceuticals Ltd make?
In fiscal 2025 Telix Pharmaceuticals Ltd reported revenue of $803.8M. That is 55.6% more than a year earlier.
When did Telix Pharmaceuticals Ltd last report?
Its most recent periodic report is the annual report (foreign issuer, amended) (20-F/A) filed on March 20, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 30, 2026.
Theses that mention TLX
Similar companies
Compare TLX with
Follow TLX
Get an email when Telix Pharmaceuticals Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Telix Pharmaceuticals Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.